Tiago Fauth
Stock Analyst at Wells Fargo
(3.12)
# 1,182
Out of 5,140 analysts
152
Total ratings
43.1%
Success rate
2.42%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $156.32 | +38.82% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $13.95 | +29.03% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $469.77 | -11.87% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.72 | +74.98% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $75.52 | -3.34% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $39.93 | -22.35% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $365.46 | +8.08% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $22.72 | +186.09% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $78.15 | -2.75% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $6.19 | +13.09% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $18.81 | +437.09% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.26 | +138.10% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $19.00 | +36.84% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.36 | +18.43% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $74.75 | +0.33% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $13.88 | +346.85% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $216.66 | -58.92% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $32.30 | +57.89% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $56.77 | +111.38% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $26.01 | -84.62% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.02 | +363.58% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $77.60 | +286.62% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.72 | +198.17% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $4.28 | +554.21% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $20.95 | +286.63% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.30 | +2,551.64% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.67 | +740.84% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $1.47 | +2,220.82% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $28.17 | +432.48% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $44.81 | -35.28% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $2.01 | +548.38% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.12 | +514.66% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.00 | +100.00% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $816.37 | -58.35% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $343.60 | -24.62% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $156.32
Upside: +38.82%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $13.95
Upside: +29.03%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $469.77
Upside: -11.87%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.72
Upside: +74.98%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $75.52
Upside: -3.34%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $39.93
Upside: -22.35%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $365.46
Upside: +8.08%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $22.72
Upside: +186.09%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $78.15
Upside: -2.75%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $6.19
Upside: +13.09%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $18.81
Upside: +437.09%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.26
Upside: +138.10%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $19.00
Upside: +36.84%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.36
Upside: +18.43%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $74.75
Upside: +0.33%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $13.88
Upside: +346.85%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $216.66
Upside: -58.92%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $32.30
Upside: +57.89%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $56.77
Upside: +111.38%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $26.01
Upside: -84.62%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.02
Upside: +363.58%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $77.60
Upside: +286.62%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.72
Upside: +198.17%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $4.28
Upside: +554.21%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $20.95
Upside: +286.63%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.30
Upside: +2,551.64%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.67
Upside: +740.84%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $1.47
Upside: +2,220.82%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $28.17
Upside: +432.48%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $44.81
Upside: -35.28%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $2.01
Upside: +548.38%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.12
Upside: +514.66%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.00
Upside: +100.00%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $816.37
Upside: -58.35%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $343.60
Upside: -24.62%